Boris D Heifets

SPIKED: Stanford Placebo vs Intraop Ketamine Evaluated for Depression. We masked ketamine with surgical anesthesia in depressed patients. Full details now published, peer review pending. Huge antidepressant response in both groups. @TheresaLii 1st auth bit.ly/3LMAueK

@KeithNHumphreys @DrDanMO The enthusiasm for fentanyl vax always puzzled me- requires motivation to quit, so why not use a simpler solution like depot naltrexone? Not to mention- so many opioid variants limit vax coverage, and I’d hate to land in an ER resistant to the most common acute care opioid

@DrDanMO I wrote about these a number of years ago for WSJ wsj.com/articles/SB100…

For a lot of people, this would be a real downer!

New preprint led by @christineliuart! How do psychedelics improve cognitive flexibility? Psilocybin prevents inflexibility caused by aberrant mesocortical error signaling (but not other mechanisms); this is tied to plasticity of PFC-MD thalamus neurons: biorxiv.org/content/10.648…

@Psyched_Alpha This is amazing —there is broad support on both sides of this issue. It would be wonderful if a small % was devoted to understanding how they work #psychedelics

We're still a ways out from the abstract deadline, but just a bump to re-advertise this great GRS that I'm co-chairing. Consciousness science is still wide open, and we intend to showcase as much of the new and interesting work in the field as we can. grc.org/consciousness-…

New in @AmJPsychiatry — personally I think this is my best paper so far. Highest statistical rigor, strongest causal inference (via a series of natural experiments), and multiple clinical applications. Thanks @KJBinSTL and team tagged below. psychiatryonline.org/doi/10.1176/ap…

Intermittent #ThetaBurst stimulation targeting the dorsomedial prefrontal cortex enhanced placebo-induced mood improvement by potentiating default mode network activity in adults with depressive symptoms. ja.ma/4gTf3JP

@theproof @AGoldPie at Stanford!

Looking for recommendations for a top sleep scientist! Ty

tenure time 🍾

The positive topline results from our Phase 3 Emerge clinical trial represent more than a company milestone, they reflect growing momentum toward potential new treatment possibilities for people living with major depressive disorder (MDD). Hear from Emerge Principal Investigator and practicing clinical psychologist, John Sonnenberg, Ph.D., who shares his perspective on the significance of these findings and how the growing body of evidence surrounding psychedelics like pharmaceutical LSD is fueling excitement and optimism across the field of psychiatry. Check out our recent press release to learn more about the Emerge Phase 3 topline data: bit.ly/4xXCOqu #MentalHealth #DefiniumTherapeutics #Psychedelics #HealthcareInnovation #MDD #Depression

Ketamine's noticeable side effects can make it difficult to know whether improvements in pain and depression come from the drug itself or from patients knowing they received it. In an early study, researchers tested a new approach using the sedative propofol to keep participants blinded to their treatment. This method could strengthen future ketamine and psychedelic research. Full paper: bit.ly/4u0pXR6

We all thought this study would fail, for different reasons. Joe Taylor (1st author) thought it'd be a takedown of fMRI-guided TMS. @foxmdphd and I (co-senior authors) thought the effect would be too small to detect in just 40 patients. We were wrong. jamanetwork.com/journals/jamap…

@DevonBuildHappy Unfortunately needs to be GMP grade, thank you though!

@TheBorisLab Some church groups provide access to blends. Psilocybin heals 🖖

Hey psychedelic researchers, do you know any company that supplies 1mg and higher quantities of psilocybin?

@DaniloDeGregor1 Human

@TheBorisLab For human studies or animals?

@Brainclinics Not yet- thx!

@TheBorisLab Have you tried Psygen: psygen.ca ?

New work on the effects of psychedelics on hierarchical cortical propagations out in PNAS! pnas.org/doi/10.1073/pn… Counter to our expectations, psychedelics attenuated bottom-up propagations into the Default Mode Network across substances and species. Thread below:

For more info visit Heifets Lab @StanfordMed, and to read the journal article, click here: journals.lww.com/anesthesiology…

What do we know about #dreaming while under surgical #anesthesia? ICYMI: Primary Care Medicine's @marinakurian & @rachel_rdn spoke with Dr. Boris Heifets @StanfordMed @TheBorisLab Tue 6/16 from 9-9:30amET LIVE about his new study in @_Anesthesiology about inducing #dreaming.

JHU PhD student Katherine Cheung and PhD Candidate Caleigh Propes, with CPCR Associate Professor Dr. David Yaden, evaluated comparison sets on the price of Oregon’s psilocybin services. As the first state in the U.S. to legalize psilocybin access and a key reference point on how other states might design psychedelic policy, this exploration helps ground discussion on Oregon’s prices in more careful analysis for future debates. bioethicstoday.org/blog/evaluatin…

CPCR Associate Director Dr. Albert Garcia-Romeu weighed in on a recent case report of psilocybin administration for an individual with suspected Alzheimer's Disease, noting some important concerns about the report: “We currently have no rigorous evidence for clinical benefits of psilocybin or other psychedelics in patients with dementia and need to proceed accordingly until we have more data.” themicrodose.substack.com/p/an-amanita-m…